New study tests if dupilumab can protect lungs in severe asthma

NCT ID NCT05097287

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dupilumab, an injectable biologic, can slow the decline of lung function in adults with uncontrolled moderate to severe asthma. Over 1,300 participants will receive either dupilumab or a placebo for three years, alongside their usual asthma medications. The main goal is to measure changes in breathing capacity over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: dupilumab
What this could lead to: If successful, this could show that dupilumab helps preserve lung function over the long term for people with uncontrolled asthma.
What could go wrong: This is a large but still ongoing study, and results are not yet available. The benefit may be modest or not apply to all patients. As with any biologic, side effects like injection site reactions or allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

1,339 people

The number who actually took part.

Started

Dec 2021

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be at least 18 (or the legal age of consent in the jurisdiction in which the study is taking place) years of age inclusive, at the time of signing the informed consent. * Patients with a physician diagnosis of asthma (according to Global Initiative for Asthma (GINA) 2021) for ≥12 months * Treatment with medium to high dose inhaled corticosteroids (ICS) in combination with a second controller (eg, long-acting beta-2 adrenergic receptor agonists (LABA), leukotriene receptor antagonists (LTRA) with a stable dose ≥1 month prior to Visit 1. Patients requiring a third controller for their asthma will be considered eligible for this study, and it should also be on stable dose ≥1 month prior to Visit 1. Patients requiring an additional controller as a fourth controller (Montelukast) for another type 2 comorbid condition such as allergic rhinitis will be considered eligible for this study, and should be on a stable dose for ≥1 month prior to Visit 1. * Pre-bronchodilator forced expiratory volume (FEV1) ≤ 80% of predicted normal for adults at Visits 1 and 2, prior to randomization * Asthma Control Questionnaire 5-question version (ACQ-5) score ≥1.5 at Visits 1 and 2, prior to randomization. * Variable airflow obstruction as documented by one or more of the following (at least 1 needs to be met): i) Positive reversibility test: ≥12% and 200 mL improvement in FEV1 after SABA administration prior to randomization, or documented in the 24 months prior to Visit 1. OR, ii) Positive bronchial challenge test: fall in FEV1 of ≥20% with standard doses of methacholine, or ≥15% with standardized hyperventilation, hypertonic saline or mannitol challenge prior to randomization or documented in the 24 months prior to Visit 1 OR, iii) Average daily diurnal Peak flow variability of \>10% over a 2-week period, documented in the past 24 months prior to Screening Visit 1. OR, iv) Airflow variability in clinic FEV1 \>12% and 200 mL between visits outside of respiratory infections, documented in the past 24 months prior to Screening Visit 1. OR v) FEV1 increases by more than 12% and 200mL from baseline after 4 weeks of anti-inflammatory treatment. * Reversibility test: Three attempts may be made during the Screening Period until the Baseline visit to meet the qualifying criteria for reversibility. This is only required if reversibility or other evidence of expiratory airflow limitation eligibility criteria was not performed within 24 months prior to Visit 1. * FeNO ≥35 ppb at Visit 2, prior to randomization. * History of ≥1 severe exacerbation(s) in the previous year before Visit1 defined as a deterioration of asthma requiring: i) Use of systemic corticosteroids for ≥3 days; or ii) Hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * History or clinical evidence of chronic obstructive pulmonary disease (COPD) including Asthma-COPD Overlap Syndrome (ACOS) or any other significant lung disease (eg, emphysema, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome). * Severe asthma exacerbation requiring treatment with systemic corticosteroid (SCS) in the past month before visit 1 or during the screening period. * Current acute bronchospasm or status asthmaticus. * Diagnosed pulmonary (other than asthma) or systemic disease associated with elevated peripheral eosinophil counts. * Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study. Examples include, but are not limited to, participants with short life expectancy, uncontrolled diabetes, cardiovascular conditions, severe renal conditions (eg, participants on dialysis), or other severe endocrinological, gastrointestinal, metabolic, pulmonary, psychiatric, or lymphatic diseases. The specific justification for participants excluded under this criterion will be noted in the study documents (chart notes, case report forms \[CRFs\], etc). * Patients with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated TB will be excluded from the study unless it is well documented by a specialist that the participant has been adequately treated and can now start treatment with a biologic agent, in the medical judgment of the Investigator and/or infectious disease specialist. Tuberculosis testing will be performed on a country by country basis, according to local guidelines if required by regulatory authorities or ethics boards, or if TB is suspected by the investigator * Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune-compromised status, as judged by the Investigator. * Active malignancy or history of malignancy within 5 years before Visit 1 (screening visit), except completely treated in situ carcinoma of the cervix and completely treated and resolved non metastatic squamous or basal cell carcinoma of the skin. * Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals or receiving only symptomatic treatment (e.g. influenza or COVID-19) within 2 weeks before the screening visit (Visit 1) or during the screening period. * History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serology at Visit 1 (screening visit). * Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use of antiparasitic drugs within 2 weeks before Visit 1 (screening visit) or during the screening and run-in period * Current smoker (cigarette or e-cigarette) or cessation of smoking within 6 months prior to Visit 1. * Previous smoker with a smoking history \>10 pack-years. * History of systemic hypersensitivity or anaphylaxis to dupilumab or any other biologic therapy, including any excipient. * Any biologic therapy (including experimental treatments and dupilumab) or any other biologic therapy/immunosuppressant/immunomodulators within 4 weeks prior to V1 or 5 half-lives, whichever is longer. * Treatment with a live (attenuated) vaccine within 4 weeks before Visit 1 (screening visit) or during the screening period. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

Advanced Respiratory and Sleep Medicine - Huntersville- Site Number : 8400056

Huntersville, North Carolina, 28078, United States
Aeroallergy Research Laboratory- Site Number : 8400114

Savannah, Georgia, 31406, United States
Allergic Disease and Asthma Center (ADAC)- Site Number : 8400026

Greenville, South Carolina, 29607, United States
Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400042

Pittsburgh, Pennsylvania, 15241, United States
Allergy & Immunology Associates of Ann Arbor- Site Number : 8400107

Ypsilanti, Michigan, 48197, United States
Allergy and Asthma Specialist- Site Number : 8400007

Owensboro, Kentucky, 42301, United States
Allergy and Asthma Specialists Medical Group- Site Number : 8400162

Huntington Beach, California, 92647, United States
Allianz Research Institute- Site Number : 8400018

Westminster, California, 92683, United States
Alpha Clinical Research Group - Dunwoody- Site Number : 8400116

Dunwoody, Georgia, 30350, United States
Andante Research- Site Number : 8400140

San Antonio, Texas, 78229, United States
Appalachian Clinical Research- Site Number : 8400129

Adairsville, Georgia, 30103, United States
Ascada Research - Fullerton- Site Number : 8400076

Fullerton, California, 92835, United States
Associacao Proar- Site Number : 0760004

Salvador, Estado de Bahia, 40060-330, Brazil
Asthma & Allergy Center - Toledo- Site Number : 8400051

Toledo, Ohio, 43617, United States
Avant Research Associates - Crowley- Site Number : 8400117

Crowley, Louisiana, 70526, United States
Beautiful Minds Clinical Research Center- Site Number : 8400141

Cutler Bay, Florida, 33157, United States
Bogan Sleep Consultants- Site Number : 8400102

Columbia, South Carolina, 29201, United States
Burke Internal Medicine and Research- Site Number : 8400170

Burke, Virginia, 22015, United States
C & R Research Services - Houston- Site Number : 8400067

Houston, Texas, 77022, United States
Cardio Pulmonary Research Center- Site Number : 8400126

Guaynabo, 00968, Puerto Rico
Central Florida Pulmonary Group - Altamonte Springs- Site Number : 8400035

Altamonte Springs, Florida, 32701, United States
Chandler Clinical Research Trials- Site Number : 8400147

Chandler, Arizona, 85224, United States
Chesapeake Clinical Research - White Marsh- Site Number : 8400119

White Marsh, Maryland, 21162, United States
Clear Brook Medical Associates- Site Number : 8400080

Houston, Texas, 77089, United States
Clinica de Alergia Martti Antila- Site Number : 0760009

Sorocaba, São Paulo, 18040-425, Brazil
Clinical Research Of Gastonia- Site Number : 8400012

Gastonia, North Carolina, 28054, United States
Cullman Research Center- Site Number : 8400001

Cullman, Alabama, 35055, United States
DM Clinical Research - 710 Lawrence Street- Site Number : 8400103

Tomball, Texas, 77375, United States
Del Sol Research Management - Tucson- Site Number : 8400017

Tucson, Arizona, 85715, United States
Discovery Clinical Trials - Dallas- Site Number : 8400123

Dallas, Texas, 75225, United States
FDI Clinical Research- Site Number : 8400121

San Juan, 00927, Puerto Rico
Family Allergy & Asthma - Louisville - Goss Avenue- Site Number : 8400160

Louisville, Kentucky, 40217, United States
Florida Center for Allergy & Asthma Research- Site Number : 8400032

Aventura, Florida, 33180, United States
Florida Lung, Asthma and Sleep Specialists (FLASS) - Polynesian- Site Number : 8400098

Kissimmee, Florida, 34746, United States
Floridian Clinical Research - Miami Lakes- Site Number : 8400091

Miami Lakes, Florida, 33016, United States
Genesis Clinical Research - Fall River- Site Number : 8400050

Fall River, Massachusetts, 02723, United States
Great Lakes Research Institute - Southfield- Site Number : 8400111

Southfield, Michigan, 48075, United States
Great Lakes Research Institute Site Number : 8400111

Southfield, Michigan, 48075-5400, United States
Health & Care - Consultancy, Research and HealthCare Management- Site Number : 0760010

Belém, Pará, 66095-055, Brazil
Health Concepts- Site Number : 8400006

Rapid City, South Dakota, 57702, United States
Heuer M.D. Research- Site Number : 8400024

Orlando, Florida, 32819, United States
Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760007

São Paulo, 01323-020, Brazil
Hospital Dia do Pulmão- Site Number : 0760002

Blumenau, Santa Catarina, 89030-101, Brazil
Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760005

Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760008

São Paulo, 05403-000, Brazil
Integrated Research of Inland- Site Number : 8400156

Upland, California, 91786, United States
IntraCare- Site Number : 8400003

Dallas, Texas, 75254, United States
Investigational Site Number : 0560002

Brussels, 1200, Belgium
Investigational Site Number : 0560003

Liège, 4000, Belgium
Investigational Site Number : 1000002

Sofia, 1233, Bulgaria
Investigational Site Number : 1000005

Dupnitsa, 2600, Bulgaria
Investigational Site Number : 1000008

Sofia, 1407, Bulgaria
Investigational Site Number : 1000009

Sofia, 1431, Bulgaria
Investigational Site Number : 1000011

Rousse, 7000, Bulgaria
Investigational Site Number : 1000012

Plovdiv, 4023, Bulgaria
Investigational Site Number : 1000013

Vratsa, 3001, Bulgaria
Investigational Site Number : 1000014

Sofia, 1756, Bulgaria
Investigational Site Number : 1240001

Toronto, Ontario, M5T 3A9, Canada
Investigational Site Number : 1240002

Québec, Quebec, G1G 3Y8, Canada
Investigational Site Number : 1240003

Windsor, Ontario, N8X 5A6, Canada
Investigational Site Number : 1240004

Vancouver, British Columbia, V6Z 1Y6, Canada
Investigational Site Number : 1240007

Toronto, Ontario, M9V 4B4, Canada
Investigational Site Number : 1240010

Moncton, New Brunswick, E1G 5C4, Canada
Investigational Site Number : 1240011

Toronto, Ontario, M5G 1E2, Canada
Investigational Site Number : 1240014

Montreal, Quebec, H1Y 3H5, Canada
Investigational Site Number : 1240015

Ajax, Ontario, L1S 2J5, Canada
Investigational Site Number : 1240017

Montreal, Quebec, H3T 1E2, Canada
Investigational Site Number : 1240018

Niagara Falls, Ontario, L2H 1H5, Canada
Investigational Site Number : 1240020

Kelowna, British Columbia, V1W 3H5, Canada
Investigational Site Number : 1240022

Vancouver, British Columbia, V5Z 1M9, Canada
Investigational Site Number : 1240023

Montreal, Quebec, H4A 3J1, Canada
Investigational Site Number : 1240024

Saskatoon, Saskatchewan, S7N 0W8, Canada
Investigational Site Number : 1240025

Sherbrooke, Quebec, J1H 5N4, Canada
Investigational Site Number : 1240028

Calgary, Alberta, T3B 0M3, Canada
Investigational Site Number : 1240029

Kingston, Ontario, K7M 7E4, Canada
Investigational Site Number : 1560001

Shanghai, 200080, China
Investigational Site Number : 1560002

Nanchang, 330006, China
Investigational Site Number : 1560003

Hebei, 050051, China
Investigational Site Number : 1560004

Tianjin, 300052, China
Investigational Site Number : 1560006

Dongguan, 523000, China
Investigational Site Number : 1560007

Guangzhou, 510000, China
Investigational Site Number : 1560008

Ningbo, 315010, China
Investigational Site Number : 1560009

Wuxi, 214023, China
Investigational Site Number : 1560010

Yueyang, 414000, China
Investigational Site Number : 1560011

Taiyuan, 030001, China
Investigational Site Number : 1560012

Taiyuan, 030032, China
Investigational Site Number : 1560013

Yichang, 443003, China
Investigational Site Number : 1560014

Nanjing, 210008, China
Investigational Site Number : 1560017

Beijing, 100029, China
Investigational Site Number : 1560019

Guiyang, 550002, China
Investigational Site Number : 1560020

Xiamen, 361004, China
Investigational Site Number : 1560021

Zhengzhou, 450003, China
Investigational Site Number : 1560022

Beijing, 100029, China
Investigational Site Number : 1560023

Hefei, 230022, China
Investigational Site Number : 1560024

Xiamen, 361004, China
Investigational Site Number : 1560025

Tianjin, 300192, China
Investigational Site Number : 1560028

Xi'an, 710004, China
Investigational Site Number : 1560029

Sichuan, 646000, China
Investigational Site Number : 1560030

Beijing, 100191, China
Investigational Site Number : 1560031

Ningbo, 315041, China
Investigational Site Number : 1580001

Kaohsiung City, 807, Taiwan
Investigational Site Number : 1580002

Taipei, 110, Taiwan
Investigational Site Number : 1580003

Douliu, 640, Taiwan
Investigational Site Number : 1580004

Taichung, 404, Taiwan
Investigational Site Number : 3000001

Thessaloniki, 570 10, Greece
Investigational Site Number : 3000002

Ioannina, 455 00, Greece
Investigational Site Number : 3000003

Athens, 106 76, Greece
Investigational Site Number : 3000004

Athens, 115 27, Greece
Investigational Site Number : 3000005

Athens, 124 62, Greece
Investigational Site Number : 3000006

Athens, 115 27, Greece
Investigational Site Number : 3000007

Athens, 115 25, Greece
Investigational Site Number : 3000008

Thessaloniki, 564 29, Greece
Investigational Site Number : 3000009

Palaió Fáliro, 175 62, Greece
Investigational Site Number : 3000010

Athens, 115 21, Greece
Investigational Site Number : 3000011

Alexandroupoli, 681 00, Greece
Investigational Site Number : 3480001

Százhalombatta, 2440, Hungary
Investigational Site Number : 3480003

Püspökladány, 4150, Hungary
Investigational Site Number : 3480004

Hajdúnánás, 4080, Hungary
Investigational Site Number : 3480005

Edelény, 3780, Hungary
Investigational Site Number : 3480006

Szombathely, 9700, Hungary
Investigational Site Number : 3480007

Mosonmagyaróvár, 9200, Hungary
Investigational Site Number : 3480008

Debrecen, 4031, Hungary
Investigational Site Number : 3480011

Budapest, 2200, Hungary
Investigational Site Number : 3480012

Budapest, 1204, Hungary
Investigational Site Number : 3480013

Szekszárd, 7100, Hungary
Investigational Site Number : 3560001

Jaipur, 302023, India
Investigational Site Number : 3560002

Kozhikode, 673008, India
Investigational Site Number : 3560003

Chandigarh, 160012, India
Investigational Site Number : 3560004

Vadodara, 390021, India
Investigational Site Number : 3560006

Mangaluru, 575003, India
Investigational Site Number : 3560008

Coimbatore, 641028, India
Investigational Site Number : 3560009

Nagpur, 440012, India
Investigational Site Number : 3560011

Ahmedabad, 380008, India
Investigational Site Number : 3560012

Nagpur, 440012, India
Investigational Site Number : 3560014

Lucknow, 226006, India
Investigational Site Number : 3560015

New Delhi, 110025, India
Investigational Site Number : 3560016

Houma, Louisiana, 70360-4413, United States
Investigational Site Number : 3560018

Mysuru, 570001, India
Investigational Site Number : 3560019

Jodhpur, 342005, India
Investigational Site Number : 3560020

Pune, 411004, India
Investigational Site Number : 3720001

Cork, T12 E8YV, Ireland
Investigational Site Number : 3720003

Dublin, D04 T6F4, Ireland
Investigational Site Number : 4100001

Seoul, Seoul-teukbyeolsi, 05030, South Korea
Investigational Site Number : 4100002

Seoul, Seoul-teukbyeolsi, 03080, South Korea
Investigational Site Number : 4100003

Seoul, Seoul-teukbyeolsi, 05505, South Korea
Investigational Site Number : 4100004

Seoul, Seoul-teukbyeolsi, 03722, South Korea
Investigational Site Number : 4100005

Seoul, Seoul-teukbyeolsi, 06351, South Korea
Investigational Site Number : 4100006

Daegu, Gyeongsangbuk-do, 42415, South Korea
Investigational Site Number : 4100007

Busan, Busan, 49241, South Korea
Investigational Site Number : 4100008

Wŏnju, Gangwon-do, 26426, South Korea
Investigational Site Number : 4100009

Seoul, Seoul-teukbyeolsi, 03312, South Korea
Investigational Site Number : 4100010

Bupyeong-Gu, Incheon-gwangyeoksi, 21431, South Korea
Investigational Site Number : 4840001

Durango, 34000, Mexico
Investigational Site Number : 4840002

Guadalajara, Jalisco, 44100, Mexico
Investigational Site Number : 4840003

Veracruz, 91900, Mexico
Investigational Site Number : 4840004

Monterrey, Nuevo León, 64460, Mexico
Investigational Site Number : 4840005

Monterrey, Nuevo León, 66465, Mexico
Investigational Site Number : 4840006

Mexico City, Mexico City, 06700, Mexico
Investigational Site Number : 4840008

Monterrey, Nuevo León, 64060, Mexico
Investigational Site Number : 4840010

Villahermosa, Tabasco, 86035, Mexico
Investigational Site Number : 4840012

Chihuahua City, 31217, Mexico
Investigational Site Number : 4840013

Oaxaca City, 68020, Mexico
Investigational Site Number : 4840014

San Juan del Río, Querétaro, 76800, Mexico
Investigational Site Number : 4840016

Chihuahua City, 31000, Mexico
Investigational Site Number : 5120001

Muscat, 111, Oman
Investigational Site Number : 5120002

Muscat, 123, Oman
Investigational Site Number : 6040001

Lima, 15001, Peru
Investigational Site Number : 6040002

Lima, 15102, Peru
Investigational Site Number : 6040003

Piura, 20000, Peru
Investigational Site Number : 6420001

Deva, 330162, Romania
Investigational Site Number : 6420002

Brasov, 500283, Romania
Investigational Site Number : 6420004

Codlea, 505100, Romania
Investigational Site Number : 6420005

Bragadiru, 769764, Romania
Investigational Site Number : 6420007

Brasov, 500051, Romania
Investigational Site Number : 6420008

Piteşti, 110117, Romania
Investigational Site Number : 6420009

Timișoara, 300134, Romania
Investigational Site Number : 6420010

Baia Mare, 430061, Romania
Investigational Site Number : 6420011

Craiova, 200515, Romania
Investigational Site Number : 6820008

Mecca, 21955, Saudi Arabia
Investigational Site Number : 7030001

Poprad, 058 01, Slovakia
Investigational Site Number : 7030002

Spišská Nová Ves, 052 01, Slovakia
Investigational Site Number : 7030003

Levice, 934 01, Slovakia
Investigational Site Number : 7030005

Topoľčany, 955 01, Slovakia
Investigational Site Number : 7100001

Cape Town, 7700, South Africa
Investigational Site Number : 7100002

Pretoria, 0009, South Africa
Investigational Site Number : 7100003

Durban, 4001, South Africa
Investigational Site Number : 7100004

Cape Town, 7764, South Africa
Investigational Site Number : 7100006

Benoni, 1500, South Africa
Investigational Site Number : 7100007

Vereeniging, 1935, South Africa
Investigational Site Number : 7100008

Somerset West, 7130, South Africa
Investigational Site Number : 7100009

Durban, 4302, South Africa
Investigational Site Number : 7100012

Chatsworth, 4092, South Africa
Investigational Site Number : 7100013

Cape Town, 7505, South Africa
Investigational Site Number : 7100014

Kempton Park, 1619, South Africa
Investigational Site Number : 7840001

Abu Dhabi, 000000, United Arab Emirates
Investigational Site Number : 7840002

Abu Dhabi, 51900, United Arab Emirates
Investigational Site Number : 7920001

Istanbul, 34098, Turkey (Türkiye)
Investigational Site Number : 7920002

Mersin, 33070, Turkey (Türkiye)
Investigational Site Number : 7920003

Adana, 01330, Turkey (Türkiye)
Investigational Site Number : 7920004

Kirikkale, 71100, Turkey (Türkiye)
Investigational Site Number : 7920006

Izmir, 35100, Turkey (Türkiye)
Investigational Site Number : 7920007

Ankara, 06620, Turkey (Türkiye)
Investigational Site Number : 7920008

Ankara, 06520, Turkey (Türkiye)
Investigational Site Number : 7920009

Kayseri, 38039, Turkey (Türkiye)
Investigational Site Number : 8260001

Newcastle upon Tyne, NE7 7DN, United Kingdom
Investigational Site Number : 8260002

Bradford, BD9 6RJ, United Kingdom
Investigational Site Number : 8260003

Oxford, Oxfordshire, OX3 9DU, United Kingdom
Investigational Site Number : 8260004

Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom
Investigational Site Number : 8260005

Liverpool, L7 8XP, United Kingdom
Investigational Site Number : 8260008

Wakefield, WF1 4DG, United Kingdom
Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760003

Porto Alegre, Rio Grande do Sul, 90020-090, Brazil
Ivetmar Medical Group- Site Number : 8400063

Miami, Florida, 33155, United States
JSV Clinical Research- Site Number : 8400150

Tampa, Florida, 33634, United States
Javara Privia Mid-Atlantic - Annapolis- Site Number : 8400087

Annapolis, Maryland, 21401, United States
Jersey City Breathing Center: Elamir Mazhar- Site Number : 8400143

Jersey City, New Jersey, 07304, United States
Kern Allergy and Medical Research- Site Number : 8400037

Bakersfield, California, 93301, United States
Lapis Clinical Research - Mooresville- Site Number : 8400112

Mooresville, North Carolina, 28117, United States
Main Street Physician's Care- Site Number : 8400077

Little River, South Carolina, 29566, United States
Medical Advancement Center of Arizona (MACOA)- Site Number : 8400130

Phoenix, Arizona, 85051, United States
Mercy Medical Group - Midtown- Site Number : 8400164

Sacramento, California, 95816, United States
Metroplex Pulmonary and Sleep Center- Site Number : 8400014

McKinney, Texas, 75069, United States
My Preferred Research- Site Number : 8400073

Miami, Florida, 33155, United States
National Allergy and Asthma - North Charleston - Northside Drive- Site Number : 8400092

North Charleston, South Carolina, 29420, United States
Newport Native MD- Site Number : 8400054

Newport Beach, California, 92663, United States
NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400138

Skokie, Illinois, 60077, United States
Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400023

DeBary, Florida, 32713, United States
Prospective Research Innovations- Site Number : 8400131

Rancho Cucamonga, California, 91730, United States
Pulmonary Associates - Deer Valley Office- Site Number : 8400155

Phoenix, Arizona, 85027, United States
REX Clinical Trials - Beaumont- Site Number : 8400135

Beaumont, Texas, 77701, United States
Research Institute of South Florida- Site Number : 8400079

Miami, Florida, 33173, United States
Revival Research Institute - Dearborn- Site Number : 8400097

Dearborn, Michigan, 48126, United States
Revive Research Institute - Lathrup Village- Site Number : 8400100

Lathrup Village, Michigan, 48076, United States
Romedica- Site Number : 8400043

Rochester, Michigan, 48307, United States
Rush University Medical Center- Site Number : 8400146

Chicago, Illinois, 60612, United States
Santa Casa de Misericordia de Belo Horizonte- Site Number : 0760006

Belo Horizonte, Minas Gerais, 30150-221, Brazil
Shoals Primary Care - Sheffield- Site Number : 8400015

Sheffield, Alabama, 35660, United States
South Texas Medical Research Institute - TTS Research- Site Number : 8400009

Boerne, Texas, 78006, United States
Southeastern Research Center- Site Number : 8400153

Winston-Salem, North Carolina, 27103, United States
St. Luke's University Hospital- Site Number : 8400099

Bethlehem, Pennsylvania, 18015, United States
Tandem Clinical Research - Metairie- Site Number : 8400163

Metairie, Louisiana, 70006, United States
Temple University Hospital- Site Number : 8400038

Philadelphia, Pennsylvania, 19140, United States
The Asthma and Allergy Center- Site Number : 8400055

Bellevue, Nebraska, 68123, United States
University of Michigan Health System - Ann Arbor- Site Number : 8400030

Ann Arbor, Michigan, 48109, United States
University of Puerto Rico - Medical Sciences Campus- Site Number : 8400128

San Juan, 00936, Puerto Rico
University of Virginia- Site Number : 8400082

Charlottesville, Virginia, 22908, United States
Urban Health Plan- Site Number : 8400144

The Bronx, New York, 10459, United States
Urgent Care Clinical Trials and KUR Research- Site Number : 8400169

Columbia, Maryland, 21045, United States
Vitality Clinical Research- Site Number : 8400142

Beverly Hills, California, 90211, United States
Woodland Clinic - Woodland- Site Number : 8400171

Woodland, California, 95695, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.